Clinical TrialJul 15, 2026, 08:42 AM
SciSparc Subsidiary NeuroThera Starts Phase IIb Trial Site for SCI-110
AI Summary
SciSparc Ltd. announced that its subsidiary, NeuroThera Labs Inc., has initiated a Phase IIb clinical trial site at Hannover Medical School in Germany for SCI-110. This proprietary cannabinoid-based treatment candidate is designed for Tourette Syndrome (TS) in adults, combining dronabinol with palmitoylethanolamide. The trial, which previously received regulatory clearance, builds on positive Phase IIa results that showed an average tic reduction of 21%. The randomized, double-blind, placebo-controlled study will also be conducted at Yale Child Study Center and Tel Aviv Sourasky Medical Center, aiming to evaluate efficacy, safety, and tolerability.
Key Highlights
- SciSparc's subsidiary NeuroThera Labs initiated a Phase IIb clinical trial site in Germany.
- The trial is for SCI-110, a cannabinoid-based treatment for Tourette Syndrome (TS) in adults.
- The German site is at Hannover Medical School, following regulatory clearance.
- SCI-110 combines dronabinol with palmitoylethanolamide to reduce tics and comorbid symptoms.
- Phase IIa study showed an average tic reduction of 21% in participants.
- The Phase IIb study is a randomized, double-blind, placebo-controlled, cross-over trial.
- Additional trial sites include Yale Child Study Center (US) and Tel Aviv Sourasky Medical Center (Israel).
- Primary efficacy endpoint is change in tic severity at weeks 12 and 26.
Price Impact
More from SPRC